From the Department of Anaesthesiology, Shengli Clinical Medical College of Fujian Medical University (YY, JL, WC, YL, XZ) and Department of Gynaecology, Fujian Cancer Hospital, Affiliated Hospital of Fujian Medical University (YS).
Eur J Anaesthesiol. 2020 Dec;37(12):1143-1149. doi: 10.1097/EJA.0000000000001270.
Dexmedetomidine is being used increasingly as a premedicant in the paediatric population. However, the effectiveness of pre-operative intranasal dexmedetomidine premedication, compared with oral midazolam, for emergence delirium is not well characterised.
To identify the effectiveness of pre-operative intranasal dexmedetomidine for emergence delirium in the paediatric patient population following general anaesthesia.
A prospective, randomised, double-blind, parallel-group, placebo-controlled trial.
Single university teaching hospital, from September 2013 to August 2014.
One hundred and fifty-six patients undergoing anaesthesia for strabismus surgery were included in the study.
Patients were randomised in a 1 : 1 : 1 ratio to receive premedication with intranasal dexmedetomidine 2 μg kg (the dexmedetomidine group), oral midazolam 0.5 mg kg (the midazolam group), or 0.9% saline (the placebo group).
The primary outcome was the incidence of emergence delirium assessed by the Paediatric Anaesthesia Emergence Delirium scale. Secondary outcomes included the quality of the inhalational induction, emergence time, postoperative pain intensity, length of stay in the postanaesthesia care unit, the incidence of postoperative nausea or vomiting (PONV) and parents' satisfaction.
The incidence of emergence delirium was lower in patients given dexmedetomidine compared with that in patients given midazolam (11.5 versus 44%, relative risk = 0.262, 95% confidence interval 0.116 to 0.592) or 0.9% saline (11.5 versus 49%, relative risk = 0.235, 95% confidence interval 0.105 to 0.525). Likewise, the incidence of PONV was lower in the dexmedetomidine group (3.8%) than that in the midazolam (22%; P = 0.006) or placebo (29.4%; P < 0.001) groups. However, there was no difference among the groups concerning postoperative pain scores and length of postanaesthesia care unit stay.
In paediatric patients undergoing strabismus surgery intranasal dexmedetomidine 2 μg kg premedication decreases the incidence of emergence delirium and PONV, and improves parents' satisfaction compared with oral midazolam.
ClinicalTrials.gov (identifier: NCT01895023).
右美托咪定在儿科人群中作为术前用药越来越多地被使用。然而,与口服咪达唑仑相比,术前鼻内给予右美托咪定预防苏醒性谵妄的效果尚不清楚。
确定术前鼻内给予右美托咪定预防全麻患儿苏醒性谵妄的效果。
前瞻性、随机、双盲、平行组、安慰剂对照试验。
2013 年 9 月至 2014 年 8 月,一所大学附属医院。
156 例接受斜视手术麻醉的患者纳入研究。
患者以 1:1:1 的比例随机接受鼻内给予右美托咪定 2μg/kg(右美托咪定组)、口服咪达唑仑 0.5mg/kg(咪达唑仑组)或 0.9%生理盐水(安慰剂组)。
主要结局指标为采用儿科麻醉苏醒期谵妄量表评估的苏醒性谵妄发生率。次要结局指标包括吸入诱导质量、苏醒时间、术后疼痛强度、术后恢复室停留时间、术后恶心或呕吐(PONV)发生率和家长满意度。
与给予咪达唑仑的患者(44%)或给予 0.9%生理盐水的患者(49%)相比,给予右美托咪定的患者苏醒性谵妄发生率较低(11.5%比26.2%,相对风险 0.262,95%置信区间 0.116 至 0.592)。同样,与咪达唑仑组(22%)或安慰剂组(29.4%)相比,右美托咪定组 PONV 发生率较低(3.8%;P=0.006)。然而,三组间术后疼痛评分和术后恢复室停留时间无差异。
在接受斜视手术的儿科患者中,与口服咪达唑仑相比,术前鼻内给予右美托咪定 2μg/kg 可降低苏醒性谵妄和 PONV 的发生率,并提高家长满意度。
ClinicalTrials.gov(标识符:NCT01895023)。